Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition

T. Machackova, H. Mlcochova, M. Stanik, J. Dolezel, M. Fedorko, D. Pacik, A. Poprach, M. Svoboda, O. Slaby,

. 2016 ; 37 (11) : 14653-14658. [pub] 20160912

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013534

Grantová podpora
NV15-34678A MZ0 CEP - Centrální evidence projektů

MicroRNAs (miRNAs) have been proven to be important oncogenes and tumor suppressors in wide range of cancers, including renal cell carcinoma (RCC). In our study, we evaluated miRNA-429 as potential diagnostic/prognostic biomarker in 172 clear cell RCC patients and as a potential regulator of epithelial-mesenchymal transition (EMT) in vitro. We demonstrated that miR-429 is down-regulated in tumor tissue samples (P < 0.0001) and is significantly associated with cancer metastasis (P < 0.0001), shorter disease-free (P = 0.0105), and overall survival (P = 0.0020). In addition, ectopic expression of miR-429 in 786-0 RCC cells followed by TGF-β treatment led to increase in the levels of E-cadherin expression (P < 0.0001) and suppression of cellular migration (P < 0.0001) in comparison to TGF-β-treated controls. Taken together, our findings suggest that miR-429 may serve as promising diagnostic and prognostic biomarker in RCC patients. We further suggest that miR-429 has a capacity to inhibit loss of E-cadherin in RCC cells undergoing EMT and consequently attenuate their motility.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013534
003      
CZ-PrNML
005      
20201116155050.0
007      
ta
008      
170413s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13277-016-5310-9 $2 doi
035    __
$a (PubMed)27619681
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Machackova, Tana $u Central European Institute of Technology (CEITEC), Masaryk University, University Campus Bohunice, Building A35, Room 217, Kamenice 5, 625 00, Brno, Czech Republic.
245    10
$a MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition / $c T. Machackova, H. Mlcochova, M. Stanik, J. Dolezel, M. Fedorko, D. Pacik, A. Poprach, M. Svoboda, O. Slaby,
520    9_
$a MicroRNAs (miRNAs) have been proven to be important oncogenes and tumor suppressors in wide range of cancers, including renal cell carcinoma (RCC). In our study, we evaluated miRNA-429 as potential diagnostic/prognostic biomarker in 172 clear cell RCC patients and as a potential regulator of epithelial-mesenchymal transition (EMT) in vitro. We demonstrated that miR-429 is down-regulated in tumor tissue samples (P < 0.0001) and is significantly associated with cancer metastasis (P < 0.0001), shorter disease-free (P = 0.0105), and overall survival (P = 0.0020). In addition, ectopic expression of miR-429 in 786-0 RCC cells followed by TGF-β treatment led to increase in the levels of E-cadherin expression (P < 0.0001) and suppression of cellular migration (P < 0.0001) in comparison to TGF-β-treated controls. Taken together, our findings suggest that miR-429 may serve as promising diagnostic and prognostic biomarker in RCC patients. We further suggest that miR-429 has a capacity to inhibit loss of E-cadherin in RCC cells undergoing EMT and consequently attenuate their motility.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a kadheriny $x genetika $7 D015820
650    _2
$a karcinom z renálních buněk $x genetika $x sekundární $x terapie $7 D002292
650    _2
$a studie případů a kontrol $7 D016022
650    12
$a pohyb buněk $7 D002465
650    _2
$a proliferace buněk $7 D049109
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a down regulace $7 D015536
650    12
$a epitelo-mezenchymální tranzice $7 D058750
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x genetika $x patologie $x terapie $7 D007680
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a lokální recidiva nádoru $x genetika $x patologie $x terapie $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a messenger RNA $x genetika $7 D012333
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a míra přežití $7 D015996
650    _2
$a transformující růstový faktor beta $x genetika $7 D016212
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mlcochova, Hana $u Central European Institute of Technology (CEITEC), Masaryk University, University Campus Bohunice, Building A35, Room 217, Kamenice 5, 625 00, Brno, Czech Republic.
700    1_
$a Stanik, Michal $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Dolezel, Jan $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Fedorko, Michal $u Department of Urology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
700    1_
$a Pacik, Dalibor $u Department of Urology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Svoboda, Marek $u Central European Institute of Technology (CEITEC), Masaryk University, University Campus Bohunice, Building A35, Room 217, Kamenice 5, 625 00, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology (CEITEC), Masaryk University, University Campus Bohunice, Building A35, Room 217, Kamenice 5, 625 00, Brno, Czech Republic. on.slaby@gmail.com. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. on.slaby@gmail.com.
773    0_
$w MED00008757 $t Tumour biology the journal of the International Society for Oncodevelopmental Biology and Medicine $x 1423-0380 $g Roč. 37, č. 11 (2016), s. 14653-14658
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27619681 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20201116155048 $b ABA008
999    __
$a ok $b bmc $g 1199999 $s 974312
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 37 $c 11 $d 14653-14658 $e 20160912 $i 1423-0380 $m Tumor biology $n Tumor Biol $x MED00008757
GRA    __
$a NV15-34678A $p MZ0
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace